S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Famous Wall Street Crash System Flashes RED (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Famous Wall Street Crash System Flashes RED (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Famous Wall Street Crash System Flashes RED (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Famous Wall Street Crash System Flashes RED (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Famous Wall Street Crash System Flashes RED (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Famous Wall Street Crash System Flashes RED (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Famous Wall Street Crash System Flashes RED (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Famous Wall Street Crash System Flashes RED (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Famous Wall Street Crash System Flashes RED (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Famous Wall Street Crash System Flashes RED (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
Famous Wall Street Crash System Flashes RED (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Famous Wall Street Crash System Flashes RED (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:SVRA

Savara (SVRA) Stock Forecast, Price & News

$2.90
-0.03 (-1.02%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.81
$2.96
50-Day Range
$1.69
$2.93
52-Week Range
$1.08
$3.01
Volume
363,493 shs
Average Volume
342,994 shs
Market Capitalization
$330.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Savara MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
20.7% Upside
$3.50 Price Target
Short Interest
Bearish
1.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Savara in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$225,636 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.30) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

631st out of 983 stocks

Pharmaceutical Preparations Industry

313th out of 486 stocks


SVRA stock logo

About Savara (NASDAQ:SVRA) Stock

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SVRA Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Savara (NASDAQ:SVRA) Upgraded at Jefferies Financial Group
From -60% Account to Doubling His Money?
After helping his readers double their money 13 TIMES in the last year alone… There’s ONE person trader Jeff Clark has NOT been able to help! His 23-year-old son, Grant.
Savara (SVRA) Gets a Buy from H.C. Wainwright
Savara (NASDAQ:SVRA) Rating Reiterated by HC Wainwright
Savara (NASDAQ:SVRA) Stock Rating Reaffirmed by HC Wainwright
Jefferies Downgrades Savara (SVRA)
Savara Announces New Leadership Appointments
Savara Announces New Employment Inducement Grant
See More Headlines

SVRA Price History

SVRA Company Calendar

Last Earnings
3/30/2023
Today
6/03/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SVRA
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.50
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+20.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-38,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$260,000.00
Book Value
$0.86 per share

Miscellaneous

Free Float
109,993,000
Market Cap
$330.80 million
Optionable
Optionable
Beta
0.84

Key Executives

  • Robert N. Neville (Age 51)
    Chairman of the Board, Chief Executive Officer
  • Taneli Jouhikainen (Age 51)
    President, Chief Operating Officer
  • David L. Lowrance (Age 50)
    Chief Financial Officer
  • Nevan C. Elam (Age 49)
    Independent Director
  • Richard J. Hawkins (Age 68)
    Independent Director
  • Joseph S. McCracken Ph.D. (Age 64)
    Independent Director
  • Matthew Pauls J.D.Matthew Pauls J.D. (Age 46)
    Independent Director
  • Yuri Pikover (Age 56)
    Independent Director













SVRA Stock - Frequently Asked Questions

Should I buy or sell Savara stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SVRA shares.
View SVRA analyst ratings
or view top-rated stocks.

What is Savara's stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month price targets for Savara's stock. Their SVRA share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price.
View analysts price targets for SVRA
or view top-rated stocks among Wall Street analysts.

How have SVRA shares performed in 2023?

Savara's stock was trading at $1.55 on January 1st, 2023. Since then, SVRA shares have increased by 87.1% and is now trading at $2.90.
View the best growth stocks for 2023 here
.

When is Savara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SVRA earnings forecast
.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) posted its earnings results on Thursday, March, 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (9.56%), AXA S.A. (2.48%), Geode Capital Management LLC (0.94%), Sio Capital Management LLC (0.83%), Jane Street Group LLC (0.25%) and Connor Clark & Lunn Investment Management Ltd. (0.18%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken, Matthew Pauls and Raymond Dennis Pratt.
View institutional ownership trends
.

How do I buy shares of Savara?

Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $2.90.

How much money does Savara make?

Savara (NASDAQ:SVRA) has a market capitalization of $330.80 million and generates $260,000.00 in revenue each year. The company earns $-38,150,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The official website for the company is www.savarapharma.com. The company can be reached via phone at 512-614-1848, via email at ir@savarapharma.com, or via fax at 858-552-0876.

This page (NASDAQ:SVRA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -